ACT Stock Recent News

Enact Holdings, Inc. (ACT) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.27 per share a year ago.

GAAP Net Income of $168 million, or $1.11 per diluted share Adjusted Operating Income of $174 million, or $1.15 per diluted share Return on Equity of 13.0% and Adjusted Operating Return on Equity of 13.4% Primary Insurance in-force of $270 billion, a 1% increase from second quarter 2024 PMIERs Sufficiency of 165% or approximately $2.0 billion Book Value Per Share of $35.20 and Book Value Per Share excluding AOCI of $35.90 Increased Full-Year Capital Return Guidance to Approximately $400 million

TARRYTOWN, N.Y.--(BUSINESS WIRE)-- #healthcaredistribution--Siemens Healthineers has earned My Green Lab ACT Ecolabel Certification for more than 150 reagents used by medical laboratories for patient testing.

INDIANAPOLIS, IN AND ST. JOHN'S ANTIGUA / ACCESS Newswire / July 18, 2025 / Arrive AI (NASDAQ:ARAI) - a pioneering autonomous delivery network anchored by Arrive Points™ - today announced an expanded partnership with AllMart - Local Marketplace & ACT Antigua, which operates a delivery service on the islands of Antigua & Barbuda.

RALEIGH, N.C., July 10, 2025 (GLOBE NEWSWIRE) -- Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced it will issue its second quarter earnings release after the market closes on July 30, 2025. Enact will host a conference call to review second quarter 2025 financial results on July 31, 2025 at 8:00 a.m. (ET).

LINDSAY, Ontario, June 05, 2025 (GLOBE NEWSWIRE) -- Today, the Advanced Coronary Treatment (ACT) Foundation joined Hydro One Inc. (Hydro One) and partners at I.E. Weldon Secondary School in Lindsay to mark the milestone of more than 25,000 Haliburton – Kawartha Lakes area students now trained through the ACT High School CPR and AED Program. This milestone reflects ACT's ongoing commitment to equip youth with the tools and confidence to act in a cardiac emergency. It also recognizes the more than 10 per cent of participants who received the new Opioid Overdose Response Training.

-       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy -       Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy -       Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK , May 6, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced that the first patient was enrolled on the trial studying Iomab-ACT targeted conditioning with a commerci

Stocks like ATKR, ACT, POOL and AWK recently announced dividend hikes.

Enact Holdings, Inc. (NASDAQ:ACT ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Daniel Kohl - Vice President of Investor Relations Rohit Gupta - President and Chief Executive Officer Dean Mitchell - Chief Financial Officer Conference Call Participants Mihir Bhatia - Bank of America Merrill Lynch Douglas Harter - UBS Richard Shane - JPMorgan Chase & Co. Bose George - Keefe, Bruyette, & Woods, Inc. Operator Hello, and welcome to Enact's First Quarter Earnings Call. Please be advised that today's conference is being recorded.

GAAP Net Income of $166 million , or $1.08 per diluted share Adjusted Operating Income of $169 million , or $1.10 per diluted share Return on Equity of 13.1% and Adjusted Operating Return on Equity of 13.4% Primary Insurance in-force of $268 billion , a 2% increase from first quarter 2024 PMIERs Sufficiency of 165% or approximately $2.0 billion Book Value Per Share of $33.96 and Book Value Per Share excluding AOCI of $34.97